Search Results

using the Breslow method. Results Sidedness Predicts Outcomes to Anti-EGFR Therapy in the Treatment-Refractory Setting A total of 62 patients were available for analysis, with baseline characteristics stratified by primary tumor sidedness

.1 (StataCorp LP, College Station, TX) and report estimates with 95% CIs. Results Patient Characteristics Among the 5,530 eligible patients (with a median age of 76 years) treated with outpatient rituximab-based immunochemotherapy in 2003

committee approved the research protocol. All participants signed informed consents. Measures Data were collected on anxiety symptoms and 5 groups of variables (demographics, disease-related characteristics, disease burden, perceived burden to others

negative predictive values (PPV and NPV, respectively); and positive and negative likelihood ratios (pLR and nLR, respectively). The receiver operating characteristic (ROC) curves were calculated, and the method proposed by DeLong et al 23 was used to test

, insurance status, marital status, and residence in metropolitan versus nonmetropolitan/rural area. Tumor characteristics included location (right-sided = cecum, ascending colon, hepatic flexure, transverse; vs left-sided = splenic flexure, descending colon

). Descriptive statistics were used to analyze the sociodemographic and clinicopathologic characteristics of each group. These variables were then compared between groups using a chi-square test. Simple logistic regression using complete-case analysis was

anecdotally described, 5 , 6 but in light of the increasing rate of publication in these types of studies, we seek to describe the characteristics of a systematic sampling of NI studies in oncology from an updated search of recent published oncology trials

association of patient, provider, and treatment team characteristics, including 1- or 2-month deadline, with the prevalence of and time to staging. Patient characteristics included age, sex, race, and Charlson comorbidity index (CCI) score. Provider

Characteristics The proportion of oncologists who received any payments within the year increased from 65.1% in 2014 to 68.7% in 2017, and the proportion who received >$10,000 within the year increased from 7.0% to 10.2% ( Table 2 ). In comparison, in 2014, 44

following characteristics: year, disease under study, phase and type (interventional/noninterventional), and sponsor type (institutional/industrial). Institutional trials included investigator-initiated trials with a local study chair or a study chair at